On the heels of a lawsuit filed by multiple medical associations, the Federal Trade Commission has delayed enforcement of the Red Flags Rule through December 31, 2010, while lawmakers consider legislation that would affect the scope of entities covered by the rule.
On the heels of a lawsuit filed by multiple medical associations, the Federal Trade Commission has delayed enforcement of the Red Flags Rule through December 31, 2010, while lawmakers consider legislation that would affect the scope of entities covered by the rule.
The American Medical Association (AMA), the American Osteopathic Association, and the Medical Society of the District of Columbia filed a lawsuit in late May to prevent the FTC from extending the rules to physicians.
The rule was developed under the Fair and Accurate Credit Transactions Act, in which Congress directed the FTC and other agencies to develop regulations requiring that all creditors, including healthcare providers, address the risk of identity theft.
The rule requires that all covered entities develop and implement written identity theft programs (see "FTC Red Flags Rule places new burden on oncology").
TABLE Red Flags Rule resources American Medical Association
www.ama-assn.org/ama/no-index/physician-resources/red-flags-rule.shtml
Federal Trade Commission
www.ftc.gov/bcp/edu/pubs/business/idtheft/bus23.shtm
Medical Group Management Association
www.mgma.com/policy/default.aspx?id=22932
Medical Oncology Association of Southern California
www.moasc.org/
The rule went into effect on January 1, 2008, with full compliance for all covered entities originally required by November 1, 2008. However, since November, the FTC has issued several delays at the behest of Congress.
According to the FTC, if Congress passes legislation limiting the scope of the Red Flags Rule with an effective date earlier than December 31, 2010, the commission will begin enforcement of the rule as of that effective date (see Table).
CECIL B. WILSON, MD
In a written statement, Cecil B. Wilson, MD, AMA president-elect, pointed out that the AMA has argued that "physicians are not creditors like banks and lenders, and the misguided Red Flags Rule should not apply to them....We hope this latest extension will be long enough for the FTC to take a good, hard look at the rule and finally exclude physicians from this unjustified and burdensome regulation of medicine."
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.